Creo Medical Group PLC First upper GI Speedboat procedure in Europe (8157D)
June 26 2023 - 1:00AM
UK Regulatory
TIDMCREO
RNS Number : 8157D
Creo Medical Group PLC
26 June 2023
Creo Medical Group plc
("Creo" the "Company" or the "Group")
First upper GI Speedboat procedure in Europe completed days
after clearance
Creo Medical Group plc (AIM: CREO), the medical device company
focused on the emerging field of surgical endoscopy, announces that
Dr Adolfo Parra-Blanco, from Nottingham University Hospital NHS
Trust has become the first clinician to perform an upper
Gastrointestinal ("GI") tract Speedboat Inject case in Europe since
clearance was gained last week.
The procedure saw a 7cm x 5cm cancerous lesion in the stomach
removed en-bloc (in one piece) in a little under two hours and was
performed after Dr Parra-Blanco led an Upper GI Endoscopy Education
and Training Day at the University of Nottingham, where he was able
to familiarise himself with the Speedboat Inject device for use in
the upper GI tract.
The result of the procedure was excellent, with the patient
leaving hospital shortly after.
A second doctor is now also trained to use Speedboat Inject for
Upper GI procedures at Nottingham, and Nottingham University
Hospital NHS Trust led Upper GI ESD courses showcasing Speedboat
are set to take place next week (June 28-30) and in August at
Queens Medical Centre, Nottingham. Creo will continue to work
closely with Nottingham University Hospital NHS Trust to support
the training, mentoring and adoption of the device by numerous
upper GI specialists over the coming months. This will be in
conjunction with Creo's Pioneer training programme, with the
Company expecting a rapid adoption of the device for upper GI
procedures over the coming months.
Dr Parra-Blanco said: "To have this technology now open to us
for use in the upper GI in Europe is fantastic. What's clear to me
is how well suited the Speedboat Inject device is for these types
of procedures, and I foresee it dramatically increasing the number
of patients able to benefit from this advanced energy, not only
here in Nottingham but at healthcare settings elsewhere across
Europe."
Craig Gulliford, Chief Executive Officer of Creo Medical said:
"To have the first case completed at such a well-respected and
prestigious endoscopic centre, renowned for its upper GI services,
so soon after clearance demonstrates both the appetite for the
device to be used in the upper GI tract in Europe and the ability
for clinicians to quickly get optimal results once they are
familiar with the advanced energy. We look forward to continuing to
work with Nottingham University Hospital NHS Trust and others to
maximise the roll out of the device in the entire GI tract."
Enquiries:
Creo Medical Group plc www.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities plc +44 (0)20 7397 8900
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Joint
Broker)
Numis Securities Limited (Joint
Broker) +44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith
/ Euan Brown
Walbrook PR Ltd Tel: + 44 ( 0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Sam Allen Mob: +44 (0)7980 541 893 / +44 (0)7502
/ Phillip Marriage 558 258 / +44 (0)7867 984 082
About Creo Medical
Creo Medical is a medical device company focused on the
development and commercialisation of minimally invasive
electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the
development and commercialisation of a suite of electrosurgical
medical devices, each enabled by CROMA, powered by Kamaptive. The
Group has developed the CROMA powered by Kamaptive full-spectrum
adaptive technology to optimise surgical capability and patient
outcomes. Kamaptive is a seamless, intuitive integration of
multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection,
coagulation and ablation of tissue. Kamaptive technology provides
clinicians with increased flexibility, precision and controlled
surgical solutions. CROMA currently delivers bipolar radiofrequency
("RF") energy for precise localised cutting and focused high
frequency microwave ("MW") energy for controlled coagulation and
ablation via a single accessory port. This technology, combined
with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and
controlled clinical solutions. The Directors believe the Company's
technology can impact the landscape of surgery and endoscopy by
providing a safer, less-invasive and more cost-efficient option for
procedures.
For more information, please refer to the website
www.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCNKPBDBBKBAAB
(END) Dow Jones Newswires
June 26, 2023 02:00 ET (06:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024